Merz to Present New Aesthetics Clinical Data at AMWC 2019

4.4.2019 11:19:00 EEST | Business Wire | Press release

Merz, a global leader in aesthetics and neurotoxins, announced today that clinical data on the use of the Merz Aesthetics portfolio, including Belotero^®, Cellfina^®, Radiesse^®, Ultherapy^® and Botulinum Toxin will be featured in oral and poster presentations at the 2019 Aesthetic & Anti-Aging Medicine World Congress (AMWC), to be held from Thursday, April 4 to Saturday, April 6, 2019 in Monte-Carlo, Monaco.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190404005258/en/

In addition to the poster presentations listed below, Merz Aesthetics is also sponsoring the Symposium event Early Intervention Meets Beautification – Treating the Social Media Generation, to be held on Friday, April 5 at 14.00h – 16.00h, Auditorium Prince Pierre. The session will include live injections and treatment insights from five international expert speakers:

Dr. Rolf Bartsch – Plastic Surgeon, Austria
Dr. Sabrina Fabi – Dermatologist, USA
Prof. Dr. Martina Kerscher – Dermatologist, Germany
Dr. Jani van Loghem – Aesthetic Physician, The Netherlands
Dr. Sonja Sattler – Dermatologist, Germany
Marie Doppelhofer – Blogger and entrepreneur, Austria

Oral Presentations

Restorative properties of hydroxylapatite (Regenerative Aesthetics Session). Kate Goldie, MBChB – European Medical Aesthetics Ltd, London, UK; Sabrina Fabi, MD, Cosmetic Laser Dermatology, San Diego, USA. Thursday, April 4, 10:00-12:00h, Auditorium Camille Blanc
Elements of the face attractiveness and balance (Fillers: Natural Results and Attractiveness Session). Dr. Jani van Loghem, MD – Falck Clinic, Amsterdam, The Netherlands. Thursday, April 4, 14:00-16:00h, Auditorium Prince Pierre
Study with controlled subcision, calcium hydroxylapatite and microfocused ultrasound with visualization: What is the best algorithm for combination to improve cellulite appearance (Rubbish and Reality on Combined Treatments Session). Gabriela Casabona, MD – Ocean Clinic, Marbella. Saturday, April 6, 9:00-10:30h, Auditorium Camille Blanc

Poster Presentations

Posters will be available for viewing at the Poster Zone on Level 2, outside of the Camille Blanc Auditorium, from Thursday, April 4 to Saturday, April 6.

Botulinum Toxin

IncobotulinumtoxinA: A unique and pure formulation of botulinum neurotoxin type A for use in aesthetic and therapeutic medicine. Ada Trindade de Almeida, MD – Hospital do Servidor Municipal de São Paulo, São Paulo, Brazil.
Comparison of incobotulinumtoxinA to botulinum neurotoxin type A formulations in Asia. Jürgen Frevert, PhD – Formerly of Merz Pharmaceuticals GmbH, Frankfurt, Germany.
Escalating doses of incobotulinumtoxinA for extended treatment of glabellar frown lines: safety and efficacy results from a randomized, double-blind study. Corey Maas, MD – The Maas Clinic, San Francisco, CA, US.
Safety, tolerability, and efficacy of repeat-dose injections of incobotulinumtoxinA in the treatment of upper facial lines: results from a prospective, open-label, phase III study. Tanja Fischer, MD – Haut- & Lasercentrum, Potsdam, Germany.
Combined post-operative scar treatment with incobotulinumtoxinA and microneedling to improve the appearance and functionality of scarring following surgical removal of facial skin tumors and flap reconstruction. Gabriela Casabona, MD – Ocean Clinic, Marbella, Spain
Decrease in therapeutic effect among botulinum toxin type A agents: Analysis of the FDA adverse event reporting system database. Rashid Kazerooni, PharmD, MS, BCPS – Merz North America, Raleigh, NC, US

Belotero ^®

Open label multicenter post-market clinical follow-up to confirm the performance and the safety of CPM^®-HA20 in facial skin revitalization. Martina Kerscher, MD, PhD – University of Hamburg, Hamburg, Germany.
Cohesive polydensified matrix crosslinked hyaluronic acid volumizing gel: An MRI and CT study. Patrick Micheels, MD – Private Practice, Geneva, Switzerland

Radiesse ^®

Diluted and Hyperdiluted Calcium Hydroxylapatite for Skin Tightening: Guidelines from a Global Consensus Panel. Kate Goldie, MBChB – European Medical Aesthetics Ltd, London, UK
Radiological evaluation of calcium hydroxylapatite implantation to correct volume loss in the dorsum of the hand. Amir Moradi, MD – Private Practice, Vista, CA, US
CaHA microspheres: Contact with fibroblasts and amount of spheres are key factors for collagen stimulation. Bartosch Nowag – Merz Pharmaceuticals GmbH, Frankfurt, Germany
Calcium hydroxylapatite: A safety review. Jonathan A. Kadouch, MD, PhD – ReSculpt Clinic, Amsterdam, The Netherlands

Ultherapy ^®

Upper Body Lifting and Tightening with Calcium Hydroxylapatite and Microfocused Ultrasound with Visualization. Jani van Loghem, MD – Falck Clinic, Amsterdam, The Netherlands
Differentiation of microfocused ultrasound with visualization treatment using a customized management protocol of see-plan-treat. Julia Sevi, MBChB – Aesthetic Health, Leeds, UK
Microfocused Ultrasound with Visualization: Treatment Plans and Comfort Management in Real-World Practice. Amanda K. Doyle, MD – Russak Dermatology, New York, NY, US

Cellfina ^®

Multicenter Pivotal Study of the Safety and Effectiveness of a Tissue Stabilized-Guided Subcision Procedure for the Treatment of Cellulite - 5 Year Update. Michael S. Kaminer, SkinCare Physicians, Chestnut Hill, MA, US

About Merz

Merz is a global, family-owned aesthetics and neurotoxin company based in Frankfurt, Germany. Privately-held for 110 years, the company is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In addition to its comprehensive portfolio of medical aesthetics products across the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2017/18, Merz generated revenue of EUR 1.024,4 million; the company has a total workforce of 3,151 employees worldwide and a direct presence in 28 countries. More information is available at www.merz.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190404005258/en/

Contact information

Media Contact
Merz Pharma GmbH & Co. KGaA
Global Communications
Mariana Smith Bourland
Phone: +49 151 4249 1466
Email: mariana.smith@merz.com
http://www.merzaesthetics.com

About Business Wire

Business Wire

http://www.businesswire.com

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

REI Super Selects SS&C For Superannuation Administration1.5.2025 06:00:00 EEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that REI Super (“REI”), the superannuation fund for Australia’s real estate industry, has signed a long-term agreement to partner with SS&C. REI selected SS&C to serve as the fund’s administrator following a competitive tender process. SS&C Global Investor & Distribution Solutions (GIDS) will provide REI with superannuation administration services and streamlined operations support to its 24,000 members across Australia. REI will benefit from SS&C’s local administration expertise, supported by its global investment in digital service channels, automation and artificial intelligence to enhance the member experience. “As one of Australia’s longest-standing superannuation funds, our focus has always been on serving our members,” said Jarrod Coysh, CEO of REI Super. “SS&C’s extensive track record in fund administration and innovative technology make them the ideal operations partner to help us best meet our members’ needs.” “W

Svante and Mercer International Advance Carbon Capture Project at Alberta Pulp Mill1.5.2025 04:25:00 EEST | Press release

Svante Technologies Inc. (Svante), a leader in carbon capture and removal technology, today announced that its joint carbon capture and storage project with Mercer International Inc. (Mercer) has advanced to the Front-end Engineering and Design Phase 2 (FEL-2). Also known as Pre-FEED, this phase involves engineering, cost estimation, and risk analysis to evaluate the project's commercial viability. Mercer is a global producer of sustainably sourced forest products, including pulp, lumber, mass timber, biomass-based green energy, and bioextractives. The carbon capture project targets biogenic CO2 emissions from Mercer’s Peace River pulp mill, where the biomass (fibre) is sourced from sustainably managed forests. Advancing to the Pre-FEED stage will support further development of the integrated design, cost estimates, and risk assessments—key steps toward a final investment decision and potential implementation. This milestone reflects the growing momentum for carbon capture solutions wi

From Scalable Solutions to Full-Stack AI Infrastructure, GIGABYTE to Present End-to-End AI Portfolio at COMPUTEX 20251.5.2025 04:00:00 EEST | Press release

GIGABYTE Technology, a global leader in computing innovation, will return to COMPUTEX 2025 from May 20 to 23 under the theme "Omnipresence of Computing: AI Forward." Demonstrating how GIGABYTE’s complete spectrum of solutions spanning the AI lifecycle, from data center training to edge deployment and end-user applications reshapes the infrastructure to meet the next-gen AI demands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428101781/en/ From Scalable Solutions to Full-Stack AI Infrastructure, GIGABYTE to Present End-to-End AI Portfolio at COMPUTEX 2025 As generative AI continues to evolve, so do the demands for handling massive token volumes, real-time data streaming, and high-throughput compute environments. GIGABYTE’s end-to-end portfolio - ranging from rack-scale infrastructure to servers, cooling systems, embedded platforms, and personal computing—forms the foundation to accelerate AI breakthroughs across industr

Carl Haney, Executive Vice President, Global Innovation and Research & Development to Depart The Estée Lauder Companies1.5.2025 01:00:00 EEST | Press release

Today, The Estée Lauder Companies Inc. (NYSE: EL) announced that Carl Haney, Executive Vice President, Global Innovation and Research & Development (R&D), will depart the company effective June 30, 2025 to pursue new opportunities. With Carl’s transition, the company intends to bring in new external talent to drive the next era of transformative innovation in line with its strategic vision of becoming the best, most consumer-centric, prestige beauty company in the world. “Over the past decade, Carl has forged impactful partnerships at the forefront of scientific innovation and delivered breakthrough products and superior formulations across categories, benefits and occasions, while fueling corporate innovation and advanced technologies,” said Stéphane de La Faverie, President and Chief Executive Officer, The Estée Lauder Companies. “As we look to the future and delivering our bold Beauty Reimagined vision, we will transform our approach to innovation across the company—which includes e

Clearwater Analytics Completes Acquisition of Beacon, Deepening Risk and Modeling Capabilities30.4.2025 23:15:00 EEST | Press release

Clearwater Analytics (NYSE: CWAN) (“Clearwater”), the most comprehensive technology platform for investment management, today announced it has completed its acquisition of Beacon Platform Inc. (Beacon), a provider of enterprise risk analytics and developer infrastructure. The acquisition strengthens Clearwater’s capabilities in complex portfolio management across both public and private markets, including structured products, private credit, and derivatives. For years, institutional investors have faced a tradeoff between advanced analytics and operational efficiency—navigating rigid legacy systems, endless manual processes, and disconnected data. These fragmented environments slow down decision-making, elevate risk, and obscure a clear, consolidated view of portfolios. Clearwater is changing that. With the integration of Beacon’s cross-asset risk modeling with front-office capabilities and alternative asset intelligence from the acquisitions of Enfusion, Inc. (Enfusion) and Blackstone

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom